Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have been assigned a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $82.73.
Several equities analysts have recently issued reports on INSM shares. Stifel Nicolaus upped their target price on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Thursday, August 29th. Truist Financial increased their price objective on Insmed from $85.00 to $100.00 and gave the company a “buy” rating in a report on Friday, October 11th. The Goldman Sachs Group increased their price objective on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. increased their price objective on Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd.
View Our Latest Report on INSM
Insmed Stock Performance
Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The firm’s revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.78) earnings per share. Equities analysts anticipate that Insmed will post -5.41 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new position in Insmed in the 3rd quarter worth approximately $30,000. EntryPoint Capital LLC bought a new stake in shares of Insmed in the first quarter worth about $33,000. Fidelis Capital Partners LLC bought a new stake in shares of Insmed in the first quarter worth about $34,000. GAMMA Investing LLC grew its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 224 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its stake in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares during the last quarter.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Stories
- Five stocks we like better than Insmed
- Ride Out The Recession With These Dividend Kings
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Calculate Stock Profit
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.